Echo Therapeutics

Newsroom

Mon, 14 Jul 2008 16:18:26 Z

<% style_additions '#middle_column li {margin-bottom: 6px; }' %>

Newsroom

Press Releases

July 14, 2008
Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony™ Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
July 1, 2008
Echo Therapeutics Initiates Clinical Study of Its Symphony™ Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
May 6, 2008
Dr. Anthony P. Furnary Joins Echo Therapeutics Medical Advisory Board
April 28, 2008
Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for
Dermatology Products and Transdermal Drug Delivery Technologies
April 9, 2008
Echo Therapeutics Announces Positive Results with the Prelude™ SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony™ Transdermal Continuous Glucose Monitoring System
Marth 25, 2008
Echo Therapeutics Announces Agreement for $2,000,000 Debt Financing
March 13, 2008
Echo Therapeutics Announces Positive Results from Symphony ™ Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
February 12, 2008
Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing
February 4, 2008
Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
January 2, 2008
Echo Therapeutics Starts Clinical Study of Its Symphony™ Continuous Transdermal Glucose Monitoring System
November 20, 2007
Echo Therapeutics Reports Third Quarter 2007 Results
October 5, 2007
Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
September 17, 2007
Sontra Medical and Echo Therapeutics Announce Merger
June 18, 2007
Sontra Medical Corporation Closes $1,000,000 Financing
May 8, 2007
Sontra Announces OTC Bulletin Board Quotation.
March 30, 2007
Sontra Medical Reports Fourth Quarter and Fiscal Year 2006 Results and Business Update.
February 21, 2007
Sontra Medical Appoints New Board Member.
January 30, 2007
Sontra Medical Corporation Closes $660,000 Financing.
January 3, 2007
Sontra Enters into Agreement for $600,000 Equity Investment.
Prior
Press Release Archive

Corporate Governance

Thu, 10 Jul 2008 17:57:29 Z

Corporate Governance

Under our corporate bylaws and Delaware General Corporation Law, Echo’s business, property and affairs are managed under the direction of the Board of Directors. Members of the Board are kept informed of Echo’s business through discussions with the Chief Executive Officer and other senior officers, by reviewing materials provided to them and by participating in meetings of the Board and its committees.

The Board maintains three committees: (1) Audit, (2) Compensation and (3) Nominating and Corporate Governance. The Board has adopted written charters for these committees, each of which can be accessed below. Each document is saved as a printable Adobe Acrobat Reader PDF file. You must have Adobe Acrobat Reader installed on your computer to read these files. Click on blue headers to access each document via PDF. If you do not have Reader, you can download a free version here.

Audit Committee Charter
The primary responsibility of the Audit Committee is to oversee Echo’s reporting processes on behalf of the Board and the stockholders and to report the results of its activities to the Board.

Compensation Committee Charter
The Compensation Committee provides assistance to the Board in fulfilling its responsibility to oversee and participate in the creation and administration of executive compensation programs and practices.

Nominating and Corporate Governance Committee Charter
The Nominating and Corporate Governance Committee provides assistance to the Board in identifying, screening and recommending qualified candidates to serve as directors of Echo. The Committee also oversees matters of corporate governance and provides counsel to the Board with respect to Board organization, membership and function.

Code of Business Conduct and Ethics
The Company also maintains a Code of Business Conduct and Ethics that is approved by the Board of Directors. A copy is provided for your reference.

Corporate Info

Thu, 10 Jul 2008 17:56:45 Z

Corporate Information

Board of Directors

Independent

Robert S. Langer, Sc.D.

Vincent D. Enright

Walter W. Witoshkin

Management

Patrick T. Mooney, MD

Shawn K. Singh, JD

SEC 10-K

Echo's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 is available free of charge by writing to:

Harry G. Mitchell
COO and CFO
Echo Therapeutics, Inc.
10 Forge Parkway
Franklin, MA 02038
<%= email 'hmitchell@echotx.com' %>

Annual Meeting

Echo's 2008 Annual Meeting of Shareholders was held on May 20, 2008, at 4:00 p.m. at the offices of Drinker Biddle Reath LLP., located at One Logan Square, 1800 Cherry Street, Philadelphia, Pennsylvania.

Transfer Agent and Registrar

Wells Fargo Shareholder Services
161 North Concord Exchange
South St. Paul, MN 55075
800.689.8788 - Telephone

Independent Auditor

Wolf & Company, P.C.
99 High Street
Boston, MA 02110

Business Overview

Thu, 10 Jul 2008 17:55:16 Z

Business Overview

Echo Therapeutics (OTCBB: ECTE) is developing its Symphony™ tCGM System, a novel, non-invasive (needle-free), wireless, transdermal continuous transdermal glucose monitoring (tCGM) system for diabetes home use and hospital critical care markets, and a pipeline of specialty pharmaceutical products incorporating its proprietary AzoneTS™ transdermal drug reformulation technology.

Echo is leveraging its unique, long-term strategic development relationship with Cato Research, a global contract research and development organization (CRO) and an affiliate of Echo's largest institutional investor, Cato BioVentures, to develop its pipleine efficiently and cost-effectively.

About Echo

Thu, 26 Jun 2008 20:58:10 Z

About Echo

Echo Therapeutics is focused on transdermal continuous glucose montioring (tCGM) systems for people with diabetes and advanced topical reformulations of FDA-approved specialty pharmaceuticals.

Echo's Symphony™ tCGM System is a next generation, non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system in development for home use and hospital critical care markets. Symphony incorporates Echo's patented feedback mechanism for optimal skin permeation control and its non-invasive, continuous transdermal biosensor. With Symphony, Echo is focused on changing the paradigm of invasive, episodic glucose testing in home use and hospital critical care settings with technology designed to improve patient compliance and achieve better overall glucose control.

Echo is leveraging its patented AzoneTS™ transdermal drug reformulation technology to build a pipeline of novel topical reformulations of FDA-approved products. Echo is developing most of its AzoneTS pipeline in accordance with the FDA's Section 505(b)(2) guidelines. Durhalieve™, Echo's lead AzoneTS drug candidate, is an AzoneTS topical reformulation of triamcinolone acetonide. Echo has submitted a New Drug Application (NDA) to the FDA covering Durhalieve as a new, proprietary treatment for corticosteroid responsive dermatoses. Echo expects to submit an Investigational New Drug (IND) application to the FDA in late-2008 to commence Phase 2 clinical development of Durhalieve for treatment of keloid scarring and hypertrophic scarring.

SonoPrep Continuous Glucose Monitoring

Tue, 22 Apr 2008 03:18:20 Z

Symphony™ tCGM System

Transdermal Continuous Glucose Monitoring (tCGM) System

Echo's Symphony™ tCGM System is a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system designed to provide reliable, on-demand blood glucose data throughout the day and night, improve patient compliance to frequent glucose testing, and achieve better overal glucose control in diabetes home use and hospital critical care markets.

Symphony for Diabetes Home Use

Diabetes is the sixth leading cause of death in the United States. Serious complications of diabetes include coronary and vascular disease, retinopathy, neuropathy and nephropathy. It is estimated that over $100 billion is spent annually in the United States for the direct and indirect costs of treating diabetes.

Most physicians who treat diabetes agree that a non-invasive, on-demand, tCGM system would greatly improve patient compliance to frequent glucose testing, which has been shown to reduce severe complications related to diabetes and health care costs, especially in hospital critical care settings. The immediate and long-term effects of inadequate blood glucose control can be devastating. Diabetes is the leading cause of kidney failure, adult blindness, non-traumatic amputations and nerve damage. When diabetes patients monitor their blood glucose frequently they can schedule their insulin injections to mimic normal physiology and reduce complications of diabetes. The non-invasive diabetes home use market is large, estimated to be $7 billion annually, and underpenetrated.

In July 2006, Echo completed its first Symphony pilot study using its ultrasound-based skin preparation device incorporating its patented feedback mechanism for optimal skin permeation control and its wireless, transdermal glucose biosensor. The pilot study involved 10 diabetes patients at an independent research laboratory. Echo's single-use glucose biosensor was placed over the ultrasound-treated skin site. The biosensor was coupled with a miniature analyzer which sent digitized data wirelessly to a monitor for data processing and display. The glucose biosensor signal was referenced to standard-of-care finger-stick blood glucose meter readings. A total of 222 data points from this pilot study were analyzed to support development of a blood glucose algorithm. The results showed that the biosensor could accurately predict blood glucose readings every minute for up to 12 hours with a single point calibration after a one hour warm-up period.

Echo’s Symphony tCGM System could address a major unmet need in the $7 billion glucose testing market. Echo's Symphony consists of a skin preparation device incorporating a patented feedback mechanism for optimal control of skin permeation, a glucose biosensor patch, a wireless transmitter and a small glucose monitor. For the diabetes home use market, Echo expects that Symphony's glucose biosensor patch will be worn under clothing to reduce lifestyle constraints. Symphony is designed to provide on-demand, continuous blood glucose readings in addition to glucose trend data and alarms that can minimize the frequency of high and low blood glucose levels. Product development is currently focused on improvements to the glucose biosensor and design of the wireless RF interface between the biosensor and glucose monitor.

Symphony for Hospital Critical Care

For post-surgical patients, tight gylcemic control has been shown in clinical studies to significantly improve outcomes by significantly reducing mortality and complications related to infections, thereby decreasing hospital stay time and cost. A primary cause of infection in critically ill patients is hyperglycemia which is a result of insulin resistance and total parenteral nutrition. Gylcemic control is achieved in the hospital critical care setting through intensive insulin therapy and hourly blood glucose measurements that record not only the absolute value, but the rate of change. A non-invasive, on-demand, continuous glucose monitor would provide better information regarding glucose trends so that insulin administration could be improved, saving valuable time for critical care nurses who spend up to 10 minutes per hour taking glucose measurements and managing insulin administration.

In December 2006, Echo completed its initial 24-hour pilot hospital critical care study at the Tufts-New England Medical Center (Tufts-NEMC) using Symphony on patients during and after cardiovascular surgery. During the pilot study, medication such as insulin and heparin were administered and blood glucose was sampled through an IV line and analyzed with a blood glucose analyzer. In the final stage of the study, a total of 147 sensor-blood glucose data points were collected and analyzed with the same blood glucose algorithm that Echo developed for its pilot diabetes home use study in July 2006. The results showed that Symphony could accurately report blood glucose readings every minute for up to 24 hours, during and after an operation.

HomePage

Fri, 18 Apr 2008 22:59:42 Z

<% full_page %><% style_additions '#middle_column {border-left: 0; padding-left: 0; padding-right: 0;} .middle_column_full { width: 800px; }' %>

Making a difference

Echo Therapeutics is a transdermal medical device and specialty pharmaceuticals company.

Echo's Symphony™ tCGM System is a next-generation, non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care markets.

Echo's AzoneTS™ transdermal drug reformulation technology is focused on building a pipeline of safer and improved versions of widely-prescribed, FDA-approved specialty pharmaceutical products. Echo is developing most of its AzoneTS pipeline in accordance with the FDA's Section 505(b)(2) guidelines. Durhalieve™, Echo's lead AzoneTS durg candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid responsive dermatoses. Echo has submitted its Durhalieve New Drug Application (NDA) to the FDA .

Echo At a Glance

Wed, 16 Apr 2008 17:07:52 Z

Echo At A Glance

Core Business:	Echo Therapeutics is a medical device and specialty pharmaceuticals company developing a next-generation, non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system for diabetes home use and hospital critical care markets and a pipeline of novel topical reformulations of FDA-approved pharmaceutial products.
Headquarters:	Echo Therapeutics, Inc 10 Forge Parkway Franklin, MA 02038 USA 508.553.8850 - Telephone 508.553.8760 - Fax
Chairman & CEO:	Patrick T. Mooney, MD
President:	Shawn K. Singh, JD
COO & CFO:	Harry G. Mitchell, CPA
OTCBB Symbol:	ECTE
Shares Outstanding:	Approximately 18.5 million
Fiscal Year End:	December 31
Core Technologies:	Echo's Symphony™ tCGM System is a next-generation, non-invasive (needle-free), wireless, tCGM system for use in diabetes home use and hospital critical care markets. Symphony incorporates Echo's patented feedback mechanism for optimal control of skin permeation and its non-invasive transdermal biosensor technologies. With Symphony, Echo is focused on reducing reliance on point-of-care periodic finger-stick glucose testing by providing reliable, on-demand glucose data continuously, conveniently and cost-effectively. Echo's goal is to change the current paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care settings with a reliable, needle-free and easy-to-use tCGM system that can improve patient compliance and achieve better overall glucose control throughout the day and night. Echo's is leveraging it AzoneTS™ skin penetration technology to develop a wide-variety of new transdermal reformulations of pharmaceutical products previously approved by the FDA. Echo has submitted a New Drug Application (NDA) to the FDA covering its lead AzoneTS-reformulated product candidate, Durhalieve™, for treatment of corticosteroid responsive dermatoses. Echo is also focused on Phase 2 development of Durhalieve for keloid scarring. Echo is developing additional AzoneTS™ product candidates in accordance with the FDA's Section 505(b)(2) guidelines.
Transfer Agent & Registrar:	Wells Fargo Shareholder Services 161 North Concord Exchange South St. Paul, MN 55075 800.689.8788 - Telephone
Independent Auditors:	Wolf & Company, P.C. 99 High Street Boston, MA 02110
General Business Inquiries:	Patrick T. Mooney, MD Chairman & Chief Executive Officer 508.553.8850 - Telephone 508.553.8760 - Fax <%= email 'pmooney@echotx.com' %>
Investor and Media Inquiries:	Lilian Stern Stern Investor Relations 212.362.1200 - Telephone 866.844.3176 - Fax
	(The information above current as of March 25, 2008)

Directors

Fri, 11 Apr 2008 23:56:08 Z

Directors

Independent

Robert S. Langer, Sc.D.

Dr. Langer is a co-founder of Sontra Medical Corporation (now Echo) and, since 1998, has served on Echo's Board of Directors. Since 1979, Dr. Langer has been Germeshausen Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. He has written 760 articles and 420 abstracts in the medical and scientific fields. In addition, Dr. Langer has 500 issued or pending patents worldwide. Dr. Langer has received over 100 major awards including the Charles Stark Draper Prize from the National Academy of Engineering and the Lemelson-MIT Prize. Dr. Langer was elected to the National Academy of Sciences and the National Academy of Engineering in 1992. Dr. Langer also serves as a director of Wyeth and Boston Life Sciences. Dr. Langer received his B.S. from Cornell University in 1970 and his Ph.D. from MIT in 1974, both in chemical engineering.

Walter W. Witoshkin

Mr. Witoshkin joined the Board of Sontra Medical Corporation (now Echo) in February 2007. He has served as Chairman and Chief Executive Officer of QuantRx Biomedical Corporation (OTCBB: QTXB) since 2005. A 40-year veteran of the pharmaceutical, healthcare and biomedical industries, Mr. Witoshkin has held senior executive positions at leading healthcare product and pharmaceutical companies, most recently SmithKline Beecham, now Glaxo SmithKline, where he was Vice President of Business Development and Chief Financial Officer. In 1989, Mr. Witoshkin established Menley & James Laboratories, Inc., after purchasing 32 SmithKline Beecham over-the-counter pharmaceutical and toiletry product brands. Menley & James had its initial public offering in 1992. He earlier held several senior finance positions at American Cyanamid, which became American Home and then Wyeth. Mr. Witoshkin joined QuantRx from Trident Group LLC, global operational consultants to the pharmaceutical and related healthcare industries. As a founding partner of Trident Group, Mr. Witoshkin specialized in alternative sourcing for manufacturing and the acquisition of technologies and products.

Vincent D. Enright

Mr. Enright joined our Board of Directors in March 2008. He has more than 30 years of financial experience with public companies, including as Senior Vice President and Chief Financial Officer of KeySpan Corporation, a NYSE public utility company. Mr. Enright currently serves as a director and Audit Committee Chairman of certain of the funds managed by Gabelli Funds, LLC, a leading mutual fund manager, positions he has held since 1991. Mr. Enright holds a B.S. degree in Accounting from Fordham.

Management

Patrick T. Mooney MD, Chairman and Chief Executive Officer

Dr. Mooney joined Echo in September 2007 as a result of the merger of Sontra Medical Corporation and then privately-held Echo Therapeutics, Inc. (ETI), for which he served as President, Chief Executive Officer and director from September 2006 through the date of the merger. Prior to joining ETI, Dr. Mooney was President, Chief Executive Officer and Chairman of Aphton Corporation (Nasdaq: APHT), where he had also served as Chief Medical Officer. Prior to that, Dr. Mooney served as Vice President, Senior Biotechnology Analyst at Thomas Weisel Partners, LLC, a full service merchant banking firm and as Vice President, Senior Biotechnology Analyst at Janney Montgomery Scott, LLC, a full services investment banking firm. Dr. Mooney received his medical degree from the Jefferson Medical College of Thomas Jefferson University and trained in surgery at Thomas Jefferson University Hospital.

Shawn K. Singh, JD, President

Mr. Singh joined Echo in September 2007 as a result of the merger of Sontra Medical Corporation and ETI, for which he served as Chairman of the Board from September 2006 through the date of the merger and as President and director from September 2004 to September 2006. Mr. Singh has been working with life science companies for nearly 20 years. In addition to his role with Echo, Mr. Singh serves, on a part-time basis, as a Principal of Cato BioVentures and, on a part-time basis, as Chief Operating Officer (Acting) and director of VistaGen Therapeutics. Prior to joining Echo, Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), founder and Managing Director of Start-Up Law, President of Artemis Neuroscience and Corporate Finance Associate in the Silicon Valley offices of Morrison & Foerster. Mr. Singh is a member of the California State Bar.

Partnering

Mon, 31 Mar 2008 17:05:32 Z

Strategic Partnering Opportunities

Echo owns all rights to its new Symphony™ tCGM System. Symphony represents a valuable, late-stage, multiple-market partnering opportunity for companies interested in building or expanding their presence in the diabetes home use market care and those focused on late-stage product opportunities for the hospital critical care market.

For companies looking for a product-life-cycle extension or a new, proprietary transdermal reformulation platform, Echo is the strategic partner of choice. Echo's AzoneTS™ transdermal reformulation platform, patented through 2019, offers reforumlation opportunities for products previously approved by the FDA. AzoneTS is a valuable life-cycle management asset for line-extensions of existing products and a renewable source of advanced formulations of FDA-approved drugs. Echo expects most of its AzoneTS pipeline programs to be amenable to the FDA's Section 505(b)(2) guidelines.

SonoPrep For Drug Delivery

Mon, 31 Mar 2008 17:02:59 Z

SonoPrep^® for Drug Delivery

The skin is the natural barrier between the outside world and the vital tissues of the human organism. Historically, transdermal drug delivery has been limited to drugs of small molecular weights. Echo's FDA-cleared SonoPrep system includes ultrasound-based skin permeation technolgy and involves a non-invasive and painless method of enhancing the flow of molecules across the skin’s membrane for up to 24 hours. Echo's application of ultrasonic energy creates reversible channels in the skin through which large molecules can be delivered. This novel use of ultrasound technology makes it possible for painless and transdermal drug delivery. These benefits may be realized through new routes for continuous transdermal drug delivery and improved patient compliance to treatment.

Clinical and pre-clinical studies have been conducted to demonstrate the safety and effectiveness of the SonoPrep system in transdermal drug delivery applications. SonoPrep skin permeation can accelerate the delivery of topical drugs and facilitate the delivery of large molecular weight protein and carbohydrate drugs such as insulin and heparin, respectively. SonoPrep has also been shown to shorten the effective onset of topical anesthetics from as long as 60 minutes to 5 minutes or less, while improving the therapeutic effect over the traditional application.

Ultrasound-based skin permeation has the potential to change the paradigm of transdermal drug delivery that limits applications to small molecules, chronic applications and potent drugs. Echo's SonoPrep enables the delivery of large MW drugs (MW > 500 Da) and accelerates the delivery of current transdermal drugs up to ten fold. Effective use of ultrasound-based skin permeation to facilitate transdermal drug delivery depends also on the application of transdermal drug formulation technologies and may be improved by combining with active transport means such as Echo's AzoneTS technology.

Echo's SonoPrep technology was invented by Dr. Robert Langer and Dr. Joseph Kost at the Massachusetts Institute of Technology (MIT). Echo licensed the technology from MIT.

SonoPrep and Transdermal Insulin

A feasibility study was performed to evaluate the use of SonoPrep ultrasound pretreatment to enable passive transdermal delivery of human recombinant insulin in an in vivo swine model. The study demonstrated that it is feasible to treat skin in a non-invasive manner using SonoPrep-based ultrasound to enable passive delivery of large protein (hexamer insulin, MW= 36 kDa at pH 7) into systemic circulation and allow the protein to express biological activities.

SonoPrep and Transdermal Heparin

The feasibility of Low Molecular Weight Heparin (LMWH) delivery through SonoPrep-pretreated skin was demonstrated in in vitro studies with porcine skin and in vivo studies in a rat model. In vivo studies in which LMWH was delivered trasndermally through ultrasonically pretreated skin demonstrated significant antifactor-X activity (aXa) well beyond 5 hours after a 2 hour lag time. In comparison, subcutaneous injection controls showed immediate activity that declined rapidly over 5 hours. Transdermal LMWH delivery exhibited prolonged activity similar to intravenous delivery.

SonoPrep for Pain Free Vein Catheterization and Phlebotomy Procedures

Intravenous (IV) catheterization and vein punctures for blood sampling are common procedures in the emergency room, operating room, nursing floors and home care settings. These procedures are performed by trained nurses and technologists who rate their performance in these procedures by their ability to minimize patient pain and anxiety.

Echo's SonoPrep and procedure tray enables healtcare workers and homecare givers to perform standard IV catheterization and phlebotomy procedures with minimal or no pain.

SonoPrep also can be used as a needle-free adjunct to IV therapy, anesthesia and pain management. SonoPrep has been shown to shorten the effective onset of topical anesthetics from as long as 60 minutes to 5 minutes or less, while improving the therapeutic effect over the traditional application.

SonoPrep System

Echo's SonoPrep system permits controlled increased skin permeability and is intended for preparing the patient with normal intact skin for therapeutic instrumentation procedures where improved permeability at a specified skin site is desirable.

The SonoPrep system operates by transferring a low level of ultrasound energy for a short time from the hand piece, causing the outer most layer of skin (stratum corneum) to become permeable. The size of the sonocation site is 0.8 cm2. Echo has conducted studies to demonstrate that skin conductivity is significantly enhanced and that the enhancement lasts for several hours. A key feature of the SonoPrep system is real-time skin conductance feedback. SonoPrep measures the increase in skin conductance (or decrease in skin impedance) during the application of ultrasound and stops the sonocation procedure when the desired level of conductance has been achieved. The SonoPrep system is indicated for the temporary disruption of the outer layer of skin prior to the application of OTC Topical 4% Lidocaine Cream for local dermal anesthesia prior to a needle insertion or IV procedure.

SonoPrep is not designed to be used on injured or otherwise compromised skin. This product is classified as CLASS 2 TYPE BF IPX0 electromedical equipment according to EN IEC 60601-1:1990. MAXIMUM RATINGS: 115 V~ 60Hz 8W.

SPECIFICATIONS
IEC Device Class:       Class 2
IEC Device Type:        Type BF
IEC Environment         Ordinary, IPX0
Device Operation       Continuous
Charger Input:             115 VAC, 60 Hz, 8 VA
Charger Output:         11.6 VDC @100 mA
Generator Output:     12 VA, 55,000 Hz
Sensor Signal: 100 mVAC, 100 Hz

OTHER LABELS/ INDICATORS
Sonocate: Indicates SonoPrep is treating the skin
Fault: Indicates the skin was not sonocated properly or completely
Low Battery: Indicates the battery needs re-charging
Charging: Indicates the battery is charging

SonoPrep Procedure Tray

The SonoPrep Procedure Tray provides the components needed to achieve effective skin permeation in less than one minute. The SonoPrep Procedure Tray consists of a SonoPrep ultrasonic coupling medium cartridge, a cleaning cartridge, a locator ring, injection site marker and two skin preparation pads.

AzoneTS

Mon, 31 Mar 2008 17:01:55 Z

AzoneTS™

Technology Overview

Echo is marshalling its AzoneTS transdermal reformulation technology to develop a pipeline of novel, proprietary reformulations of FDA-approved pharmaceutical products.

Compared to oral formulations, Echo’s AzoneTS transdermal reformulation technology can:

Provide once-daily to once-weekly delivery systems with steady drug action;
Eliminate first-pass metabolism;
Introduce less drug into the body to achieve therapeutic blood levels;
Increase patient compliance and convenience;
Reduce food and systemic drug interactions and associated side effects; and
Reduce certain forms of drug abuse.

Echo believes its AzoneTS transdermal drug delivery platform has the potential to expand the number of drugs – in many more therapeutic categories – that can be delivered transdermally.

Properties

AzoneTS is an effective, nontoxic, penetration enhancer that is known to increase lipid membrane fluidity in the stratum corneum, thereby decreasing the diffusion resistance to topically applied therapeutics. AzoneTS is a chemical combination of pyrolidone and decylmethyl sulfoxide, both of which alone act as weak penetration enhancers. Echo’s proprietary synergistic chemical combination enables AzoneTS to be a highly effective penetration enhancer at low concentration levels. When combined with AzoneTS, the penetration of numerous FDA-approved drugs is improved from two to more than twenty fold.

AzoneTS has been used as a penetration enhancer in 32 human clinical studies, 72 animal studies, and has proven to be a safe, nonirritating and clinically effective transdermal penetration enhancer.

4/48 Program™

Echo expects FDA approval of Durhalieve™ to be a watershed event in its effort to monetize its AzoneTS transdermal drug delivery platform, resulting in multiple AzoneTS product development and marketing partnership opportunities. Upon US market approval of Durhalieve™, Echo believes it will be positioned to offer its pharmaceutical partners a highly efficient and relatively low cost, advanced topical reformulation alternative for their FDA-approved oral and injectable specialty pharmaceutical products.

Echo’s AzoneTS 4/48 Program contemplates a $4 million, 48-month pipeline-to-NDA filing product development model in accordance with the FDA's Section 505(b)(2) guidelines, as executed by Echo and Cato Research.

Durhalieve™

Durhalieve™ is Echo’s lead AzoneTS product candidate. Durhalieve is a topical AzoneTS reformulation of triamcinolone acetonide, a widely-used, medium potency corticosteroid approved by the FDA for treatment of corticosteroid-responsive dermatoses. Echo has filed a New Drug Application (NDA) with the FDA seeking market approval for Durhalieve for treatment of corticosteroid-responsive dermatoses. Echo is in discussions with the FDA regarding the manufacturing requirements remaining to secure FDA approval of Durhalieve.

Test2

Thu, 27 Mar 2008 14:45:06 Z

Test

Thu, 27 Mar 2008 14:44:30 Z

Pipeline Test

Symphony CTGM System Pipeline

AzoneTS Pipeline

Management Presentations

Thu, 13 Mar 2008 16:47:21 Z

<% style_additions '#middle_column li {margin-bottom: 6px; }' %>

Management Presentations

March 13, 2008
Echo Therapeutics Symphony Results
   For replay until March 16th call:
   - USA & Canada: 800-642-1687
   - International: 706-645-9291
   Conference code: 39282879
February 7, 2008
RedChip Small-Cap Investor Conference

Echo Therapeutics

Newsroom

Newsroom

Press Releases

Corporate Governance

Corporate Governance

Corporate Info

Corporate Information

Board of Directors

Independent

Management

SEC 10-K

Annual Meeting

Transfer Agent and Registrar

Independent Auditor

Business Overview

Business Overview

About Echo

About Echo

SonoPrep Continuous Glucose Monitoring

Symphony™ tCGM System

Transdermal Continuous Glucose Monitoring (tCGM) System

Symphony for Diabetes Home Use

Symphony for Hospital Critical Care

HomePage

Making a difference

Echo At a Glance

Echo At A Glance

Directors

Directors

Independent

Robert S. Langer, Sc.D.

Walter W. Witoshkin

Vincent D. Enright

Management

Patrick T. Mooney MD, Chairman and Chief Executive Officer

Shawn K. Singh, JD, President

Partnering

Strategic Partnering Opportunities

SonoPrep For Drug Delivery

SonoPrep® for Drug Delivery

SonoPrep and Transdermal Insulin

SonoPrep and Transdermal Heparin

SonoPrep for Pain Free Vein Catheterization and Phlebotomy Procedures

SonoPrep System

SonoPrep Procedure Tray

AzoneTS

AzoneTS™

Technology Overview

Properties

4/48 Program™

Durhalieve™

Test2

Test

Pipeline Test

Symphony CTGM System Pipeline

AzoneTS Pipeline

Management Presentations

Management Presentations

SonoPrep^® for Drug Delivery